Saturday 17 October 2026
Export CLLS’s income statement to Excel — free account
Cellectis S.A.
CLLS Healthcare Biotechnology
Cellectis S.A.’s revenue for fiscal 2025 (year ended December 2025) was $79.6 million, up 61.7% from fiscal 2024. In the quarter to June 2026, revenue fell 62.1%, EPS grew 8.33%, free cash flow fell 37.0% and total debt was flat, each against the same quarter a year earlier.
1.04
0.07
−6.31%
Follow CLLS
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 3 | 1 | 5 | 3 | 1 | 1 | 7 | 2 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
11.32 | 31.85 | 31.68 | 31.61 | 13.95 | 9.43 | 4.02 | 19.04 | 3.31 | 6.10 |
Altman Z-Score |
5.59 | 11.47 | 7.33 | 2.39 | 2.79 | (1.30) | (2.59) | (1.93) | (0.82) | (0.03) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.51 | 0.00 |
Altman Z″-Score (non-manufacturers) |
6.08 | 6.24 | 11.07 | 2.63 | 0.40 | (3.05) | (4.78) | (4.03) | (1.23) | (1.89) |
P/Operating CF |
384.12 | (112.89) | (32.95) | (252.12) | (33.94) | (17.26) | (84.75) | 4.41 | (3,468.49) | (46.85) |
Beneish M-Score |
(3.00) | (2.98) | (1.50) | 3.40 | (0.44) | (0.32) | (3.48) | (2.37) | 0.00 | (2.61) |
P/B ratio |
2.33 | 3.78 | 1.51 | 2.04 | 3.72 | 1.54 | 0.82 | 2.07 | 1.24 | 6.39 |
Price to Tangible BV |
2.34 | 3.80 | 1.51 | 2.05 | 3.74 | 1.55 | 0.83 | 2.08 | 1.25 | 6.44 |
EV/Sales |
6.20 | 23.05 | 10.65 | 17.98 | 11.13 | 5.19 | 1.22 | 2.79 | (0.62) | 4.54 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.76 | 0.00 |
EV/Operating CF |
(10.69) | (14.85) | (3.35) | (5.98) | (11.43) | (1.91) | (0.36) | (1.04) | (1.32) | (9.17) |
EV/FCF |
(7.49) | (16.25) | (3.18) | (5.06) | (7.25) | (1.63) | (0.35) | (0.93) | (1.58) | (8.18) |
Quick Ratio |
5.40 | 6.80 | 10.07 | 5.96 | 5.46 | 4.37 | 1.79 | 1.45 | 1.69 | 1.58 |
Current Ratio |
5.56 | 7.11 | 10.40 | 6.25 | 6.06 | 4.57 | 2.28 | 1.50 | 1.73 | 1.62 |
Net Debt/EBITDA |
4.45 | 3.33 | 4.39 | 2.68 | 3.08 | 1.83 | 1.01 | 1.90 | 4.87 | 9.54 |
Debt/Assets |
0.53% | 0.01% | 0.27% | 10.19% | 7.58% | 5.86% | 9.81% | 16.28% | 17.47% | 26.01% |
Debt/Equity |
0.01 | 0.00 | 0.00 | 0.13 | 0.12 | 0.09 | 0.20 | 0.64 | 0.51 | 1.11 |
Asset Turnover |
0.16 | 0.10 | 0.05 | 0.05 | 0.18 | 0.09 | 0.08 | 0.03 | 0.14 | 0.22 |
Operating CF/Net income |
0.49 | 0.53 | 0.87 | 0.68 | 0.99 | 0.92 | 0.82 | 0.24 | (0.63) | 0.58 |
Capex/Depreciation |
(6.34) | 1.34 | (1.52) | (1.82) | (4.71) | (1.31) | (0.13) | (0.06) | (0.19) | (0.18) |
Interest Coverage |
(9.48) | (5.06) | (27.56) | (34.03) | (4.88) | (15.95) | (5.03) | (2.39) | (2.76) | (0.65) |
| (23.71%) | (35.57%) | (21.43%) | (25.34%) | (24.41%) | (41.88%) | (58.57%) | (95.96%) | (34.08%) | (65.33%) | |
| (18.94%) | (29.92%) | (18.88%) | (21.09%) | (17.31%) | (26.82%) | (33.00%) | (33.94%) | (10.24%) | (19.09%) | |
ROIC |
0.00% | 0.00% | 0.00% | (182.91%) | (70.08%) | (88.93%) | (104.04%) | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(24.62%) | (34.87%) | (17.46%) | (28.95%) | (24.20%) | (44.80%) | (73.48%) | (76.25%) | (22.05%) | (52.28%) |
Average Days of Receivables |
79.86 | 132.91 | 343.06 | 192.09 | 70.27 | 280.19 | 216.63 | 852.41 | 157.48 | 101.80 |
Research and Development Expense of Revenue |
139.00% | 234.99% | 357.26% | 400.36% | 105.45% | 305.31% | 379.01% | 953.40% | 183.95% | 117.50% |
Selling, General and Administrative Expense of Revenue |
76.91% | 132.73% | 220.46% | 187.11% | 53.61% | 59.28% | 68.00% | 182.88% | 38.78% | 24.86% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
103.86% | 149.54% | 173.66% | 116.92% | 20.30% | 29.78% | 23.49% | 56.92% | 6.43% | 7.68% |
Graham Net Nets |
0.40 | 0.26 | 0.64 | 0.38 | 0.13 | 0.22 | 0.08 | (0.09) | 0.21 | (0.03) |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(10.49%) | (9.27%) | (11.71%) | (14.08%) | (7.21%) | (31.16%) | (103.08%) | (56.03%) | (33.33%) | (13.93%) |
Free Cash Flow Yield |
(7.31%) | (4.45%) | (10.57%) | (11.24%) | (11.00%) | (33.83%) | (86.13%) | (15.71%) | 11.74% | (9.10%) |
Revenue per Share |
1.60 | 0.94 | 0.53 | 0.54 | 1.94 | 0.86 | 0.56 | 0.16 | 0.54 | 0.79 |
Operating CF per Share |
(0.93) | (1.47) | (1.67) | (1.63) | (1.89) | (2.33) | (1.92) | (0.43) | 0.25 | (0.39) |
Capex per Share |
(0.40) | 0.13 | (0.09) | (0.30) | (1.09) | (0.41) | (0.05) | (0.02) | (0.04) | (0.04) |
Free Cash Flow per Share |
(1.32) | (1.34) | (1.76) | (1.92) | (2.98) | (2.75) | (1.97) | (0.45) | 0.21 | (0.43) |
Cash per Share |
8.25 | 8.32 | 11.08 | 8.50 | 6.31 | 4.15 | 2.14 | 3.57 | 2.87 | 2.08 |
Shareholders Equity per Share |
7.79 | 7.96 | 11.04 | 8.38 | 7.27 | 5.28 | 2.77 | 1.49 | 1.45 | 0.76 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
7.79 | 7.96 | 11.04 | 8.38 | 7.27 | 5.28 | 2.77 | 1.49 | 1.45 | 0.76 |
Free Cash Flow |
(46.72) | (47.82) | (71.76) | (81.69) | (126.47) | (123.12) | (89.88) | (25.82) | 19.15 | (42.93) |
Working Capital |
256.33 | 277.77 | 440.77 | 328.92 | 263.35 | 176.08 | 80.82 | 77.86 | 120.80 | 90.49 |
Capital Expenditures |
(14.01) | 4.51 | (3.62) | (12.54) | (46.21) | (18.56) | (2.44) | (1.07) | (3.84) | (3.53) |
Net Current Asset Value |
255.74 | 274.32 | 437.07 | 279.52 | 154.74 | 79.83 | 8.54 | (16.57) | 34.56 | (12.57) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.51 | 0.00 |
Capex to Sales |
0.25 | (0.13) | 0.17 | 0.55 | 0.56 | 0.48 | 0.09 | 0.12 | 0.08 | 0.04 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.13 | 0.47 | 0.24 | 0.29 | 0.14 | 0.18 | 0.29 | 0.34 | 0.43 | 0.52 |
Cash ROIC |
(8.23%) | (8.23%) | (7.94%) | (10.69%) | (20.64%) | (27.67%) | (36.06%) | (7.53%) | 4.18% | (11.63%) |
Accounts Receivable Turnover |
3.87 | 2.74 | 1.32 | 1.43 | 5.90 | 1.70 | 1.15 | 0.50 | 2.31 | 3.67 |
Accounts Payable Turnover |
0.21 | 0.27 | 0.22 | 0.50 | 1.35 | 0.08 | 0.08 | 0.04 | 0.00 | 0.00 |
Inventory Turnover |
12.11 | 14.24 | 10.43 | 7.18 | 16.11 | 0.00 | 0.00 | 0.00 | — | — |
Average Days of Payables |
1,996.92 | 1,317.90 | 2,116.57 | 937.62 | 247.62 | 4,703.43 | 4,419.55 | 9,443.94 | 0.00 | 0.00 |
Days of Inventory on Hand |
24.24 | 34.83 | 36.65 | 92.82 | 16.16 | 0.00 | 0.00 | 0.00 | — | — |
Average Receivables |
14.58 | 12.31 | 16.21 | 16.12 | 13.99 | 22.75 | 22.45 | 18.37 | 21.35 | 21.72 |
Average Payables |
8.53 | 9.59 | 12.67 | 22.57 | 26.94 | 24.19 | 22.61 | 20.26 | 18.87 | 17.97 |
Average Inventory |
0.15 | 0.18 | 0.26 | 1.59 | 2.25 | — | — | — | — | — |
Average Assets |
355.07 | 332.16 | 416.86 | 484.15 | 468.47 | 425.77 | 321.65 | 297.74 | 358.91 | 354.13 |
Average Common Equity |
283.70 | 279.33 | 367.13 | 402.87 | 332.16 | 272.66 | 181.21 | 105.32 | 107.86 | 103.47 |
Columns are period end dates